Hematology - European Medical Journal
×

Browse

Hematology

articles
13
Nov

Is Allogeneic Stem Cell Transplantation a Good Option for Paroxysmal Nocturnal Haemoglobinuria?
Hematology
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare disease of nonmalignant clonal haematopoietic stem cells with an estimated prevalence of 1–16 cases per million, which may be underestimated because of undiagnosed patients…
EMJ Hematology 8 [Supplement 5] 2020 Feature Image
24
Sep

The Impact of Sickle Cell Disease: Updates in Therapeutics, Treatment, Management, and Future Directions
Hematology
Although VOC are the hallmark of SCD, a lack of VOC events does not prevent chronic multi-organ damage. Patients with sickle cell anaemia (SCA)…
EMJ Hematology 8 [Supplement 4] 2020 Feature Image
18
Sep

European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukaemia: Implications for Ponatinib
Hematology
Ponatinib is indicated for the treatment of adults with chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, are intolerant…
EMJ 5.3 2020
17
Sep

Economic Evaluation of Severe Anaemia: Review-Based Recommendations and a Conceptual Framework
Hematology
Anaemia is characterised by a decrease in the total amount of red blood cells (RBC) and haemoglobin (Hb) levels, reducing the volume of oxygen transported through the blood…
hematology 8.1 featured image
30
Jul

Doing More for Patients with Immune Thrombocytopenia: Putting New Recommendations into Practice
Hematology
The American Society of Hematology (ASH) guidelines and the International Consensus Report (ICR) recommendations were first published in 2010 and 2011…
hematology 8.1 featured image
30
Jul

Outcomes for Patients with High-Risk Acute Myeloid Leukaemia: Can We Move from Months to Years?
Hematology
This symposium focussed on the recognition of, and treatment options for, high-risk AML. Prof Cluzeau considered universal or targeted treatment…
hematology 8.1 featured image
30
Jul

AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukaemia and an IDH1 Mutation
Hematology
Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate…
hematology 8.1 featured image
30
Jul

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib, with the BCL2-Inhibitor Venetoclax +/-Azacitidine in IDH1-Mutated Myeloid Malignancies
Hematology
Venetoclax is a potent, selective, oral inhibitor of B-cell lymphoma-2. It is approved in the USA in combination with azacitidine, decitabine…